Chardan Capital Markets analyst Gbola Amusa lowered the price target on Provention Bio Inc. (NASDAQ: PRVB) to $22.50 (from $35.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Pre-Open Stock Movers 05/28: (AMC) (ITRM) (YEXT) Higher; (PRVB) (HPQ) (BIG) Lower (more...)May 28, 2021 9:25 AM Provention Bio Inc. (PRVB) to Resume Trading at 7:10 a.m.May 28, 2021 7:08 AM Provention Bio (PRVB) Confirms FDA Advisory Committee Votes in Favor of Benefits of Teplizumab Outweighing Risks in Support of Approval to Delay Clinical Type 1 DiabetesMay 28, 2021 7:07 AM Form 8-K Provention Bio, Inc. For: May 27May 28, 2021 6:08 AM